Original Article
Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus
N Engl J Med 1994; 330:15-18January 6, 1994
- Abstract
Background
The high relative mortality among patients with insulin-dependent diabetes mellitus results mainly from diabetic nephropathy. The cumulative incidence of nephropathy of 25 to 30 percent among patients who had had diabetes for 25 years remained stable from 1950 to the early 1980s. In a population study, we assessed recent trends in the incidence of diabetic nephropathy.
Methods
We studied all 213 patients in whom insulin-dependent diabetes mellitus was diagnosed before the age of 15 years between 1961 and 1980 in a district in southeastern Sweden. Ninety-two percent of the patients were followed from the onset of diabetes to 1991 or to death. Patients with persistent albuminuria (positive Albustix test) were considered to have diabetic nephropathy. Glycosylated hemoglobin was measured periodically in all patients, beginning in 1980.
Results
The cumulative incidence of persistent albuminuria after 25 years of diabetes decreased from 30.0 percent among the patients in whom diabetes developed in the period 1961 to 1965 to 8.9 percent among those in whom it developed from 1966 to 1970 (P = 0.01). After 20 years of diabetes, the cumulative incidence decreased from 28.0 percent among the patients in whom diabetes developed from 1961 to 1965 to 5.8 percent among those in whom it developed from 1971 to 1975 (P = 0.01). Persistent albuminuria has not yet developed in any patient in whom diabetes was diagnosed in the period 1976 to 1980. The average glycosylated hemoglobin value decreased from 7.4 percent in the period 1980 to 1985 to 7.0 percent from 1986 to 1991 (P<0.001). The mean glycosylated hemoglobin value was higher in the patients with persistent albuminuria than the patients with no albuminuria (8.1 percent vs. 7.1 percent, P<0.001).
Conclusions
During the past decade the cumulative incidence of diabetic nephropathy, as manifested by persistent albuminuria, among patients who have had diabetes for 25 years has decreased substantially, probably as a result of improved glycemic control.
Media in This Article
Figure 1
Cumulative Incidence of Persistent Albuminuria among Patients in Whom Insulin-Dependent Diabetes Began before the Age of 15 Years, According to the Year of Onset.Table 1
Clinical Characteristics of Patients with Insulin-Dependent Diabetes Mellitus Occurring before the Age of 15 Years.Article Activity
- Article
Diabetic nephropathy is the most common cause of end-stage renal failure in the Western world1. Among patients with insulin-dependent diabetes, those with proteinuria are at greatest risk for early death2,3. The cumulative incidence of nephropathy among patients with diabetes for 25 years decreased between 1940 and 1950, from 40 percent to 25 to 30 percent, and then remained stable until the 1980s4,5.
There have been substantial changes in the treatment of diabetes in the past 20 years. Self-monitoring by measurement of urinary glucose and, more recently, blood glucose has become routine; together with better education and better adjustment of treatment to the patient's lifestyle, self-monitoring has led to improved metabolic control. Using these methods of management, we began a prospective, population-based, long-term follow-up study of complications in young patients less than 15 years old with insulin-dependent diabetes, starting in 1973 at the University Hospital in Linkoping, Sweden. We report here on the incidence of diabetic nephropathy among patients with diabetes diagnosed in two decades (from 1961 to 1980) and the importance of glycemic control in relation to the development of nephropathy.
Methods
Patients
We studied all 213 patients with insulin-dependent diabetes beginning before the age of 15 years who lived within the catchment area of the Pediatric Clinic, University Hospital, Linkoping, Sweden, between 1961 and 1980.
During the 1960s, the standard insulin regimen consisted of a single morning dose of long-acting insulin, sometimes with a dose of short-acting insulin. Patients were advised to eat regular meals and to limit their intake of simple carbohydrates and fat. In 1971 a team that included physicians, a nurse who educated patients about their diabetes, a dietitian, a social worker, and later a psychologist was formed at the clinic. Patients were seen at least every three months until they left school at the age of 18 to 20 years, at which time their care was transferred to the Department of Internal Medicine, where the same routines were followed. The number of daily insulin injections increased from one to two in the 1970s to two to five in the 1980s, a change facilitated by the introduction of pen-type injectors in 1984. As multiple injections were introduced, the proportion of patients receiving short-acting insulin increased from 10 to 20 percent in the early 1970s to 60 percent in the 1980s, and some patients used insulin pumps during the latter period. Regular self-monitoring of urinary glucose three times daily became routine in 1971, and self-monitoring of blood glucose and periodic measurement of glycosylated hemoglobin began in 1980. Psychosocial support, group education, camps, and regular evening lectures for parents also became important elements of the treatment program in the early 1970s6.
Measurement of Urinary Protein
In all, 197 of the patients (92.5 percent) were followed from the onset of diabetes to 1991 or death (10 patients). The remaining 16 patients (7.5 percent) were followed until their most recent clinic visit.
All patients were tested for proteinuria at their regular clinic visits, with the use of reagent-impregnated strips (Albustix, Ames, Bridgend, United Kingdom). The 154 patients who still lived in our catchment area were invited to make a special follow-up visit during the period 1990 to 1992, and were asked to collect three timed overnight urine samples for measurement of the albumin excretion rate. Of these patients, 122 (79.2 percent) completed the tests; the remaining 32 patients were examined at routine clinic visits. Thirty of the 49 patients who had moved out of the area responded to a questionnaire and provided data (through their physicians) on albumin excretion rates and antihypertensive treatment.
For the purposes of this study, diabetic nephropathy was defined as persistent albuminuria (a 1+ test result with Albustix, equivalent to the excretion of ≥ 300 mg of albumin per liter). The first year during which albuminuria became persistent was defined as the year of onset of diabetic nephropathy. Microalbuminuria was defined as the excretion of 20 to 200 μg of albumin per minute in at least two of the three timed overnight urine samples collected from 1990 to 1992. The patients were divided into four groups according to year of diagnosis of diabetes: 1961 to 1965, 1966 to 1970, 1971 to 1975, and 1976 to 1980. The groups were similar in their numbers of patients, sex distribution, mean age at onset of diabetes, and percentage followed (Table 1Table 1
Clinical Characteristics of Patients with Insulin-Dependent Diabetes Mellitus Occurring before the Age of 15 Years.).The study was approved by the Ethics Committee of the Medical Faculty at the University of Linkoping, and all patients gave informed consent for the studies in 1990 through 1992.
Measurement of Glycosylated Hemoglobin
Glycosylated hemoglobin was determined by ion-exchange chromatography. Between 1980 and 1982, minicolumns were used (Quicksep, Isolab, Akron, Ohio) and the analysis included the labile Schiff-base fraction. From 1982 to 1984 the same method was used after the labile fraction had been eliminated. After 1984 glycosylated hemoglobin was measured by high-performance liquid chromatography (HPLC:Auto A1c HA8810, Kyoto Daichi, Kyoto, Japan). Corresponding values for hemoglobin A1c were calculated from intermethod calibration by the analyzing laboratory. The normal range was 3.2 to 6.0 percent. All values for glycosylated hemoglobin in each patient, a total of 3688 measurements, were included in the analysis. Patients who moved out of the area or died were not included in the analyses of differences in the degree of glycemic control between 1980 and 1985 and between 1986 and 1991 because of difficulties in calculating corresponding values for glycosylated hemoglobin measured at different laboratories.
Statistical Analysis
The cumulative incidence of diabetic nephropathy was calculated for one-year intervals with a life-table method that took into account differences in the interval of follow-up after the first visit. Patients in whom nephropathy did not develop were followed until their examination in the period 1990 to 1992 if they were studied then, the year of their last clinic visit, or the year of death. The calculations were performed according to the algorithm of Lee and Desu (1972) with the SPSS Statistical Package for the Social Sciences7. When incidence rates for the periods 1971 to 1975, 1976 to 1980, 1981 to 1985, and 1986 to 1990 were compared, the duration of diabetes was standardized in five-year intervals by an indirect standardization method. The paired t-test (two-tailed) was used to compare the mean values for glycosylated hemoglobin in each patient during 1980 to 1985 and 1986 to 1991. The average values for glycosylated hemoglobin in patients with persistent albuminuria were compared with those in patients without this feature by an unpaired t-test (two-tailed).
Results
The cumulative incidence of persistent albuminuria in the patients in whom diabetes developed between 1961 and 1965 started to increase after 8 years, reached 28.0 percent after 20 years, and peaked at 23 years, when it reached 30.0 percent (Figure 1Figure 1
Cumulative Incidence of Persistent Albuminuria among Patients in Whom Insulin-Dependent Diabetes Began before the Age of 15 Years, According to the Year of Onset.). The incidence remained at that level until the end of the study period. The patients in whom diabetes began between 1966 and 1970 had a cumulative incidence of persistent albuminuria of 8.9 percent after having had diabetes for 20 years; no new cases of persistent albuminuria developed thereafter (P = 0.01, as compared with the incidence in patients with onset of diabetes between 1961 and 1965). In the patients in whom diabetes developed between 1971 and 1975, the cumulative incidence after they had had diabetes for 10 years was 5.8 percent, and it remained constant thereafter to the end of the observation period. The difference in the cumulative incidence between the group with onset of diabetes between 1961 and 1965 and the group with onset between 1971 and 1975 (28.0 percent vs. 5.8 percent) was also significant (P = 0.01). No patient in whom diabetes was diagnosed between 1976 and 1980 had persistent albuminuria during the study period.The risk of persistent albuminuria increased considerably between the 8th and 17th years after the onset of diabetes and declined thereafter in each of the four groups. The incidence declined by three quarters from the 1970s to the period 1986 to 1991. The prevalence of microalbuminuria was similar in the four groups at the time of follow-up: 8.6 percent in patients in whom diabetes was diagnosed from 1961 to 1965, 11.9 percent in those given a diagnosis from 1966 to 1970, 5.9 percent in those given a diagnosis from 1971 to 1975, and 7.8 percent in those given a diagnosis from 1976 to 1980.
The degree of glycemic control as assessed from the glycosylated hemoglobin values improved during the 1980s (Table 2Table 2
Glycosylated Hemoglobin Values in Patients with Insulin-Dependent Diabetes Mellitus.). The glycosylated hemoglobin values decreased significantly between 1980 and 1985 and between 1986 and 1991 in the three groups in which diabetes developed from 1961 to 1975. The group in which diabetes developed from 1976 to 1980 had mean values throughout the 1980s that were similar to those in the three other groups between 1986 and 1991. The patients who did not have microalbuminuria in the period 1990 to 1992 had significantly lower mean glycosylated hemoglobin values between 1981 and 1991 than the patients with microalbuminuria or the patients with persistent albuminuria (mean [±SE], 7.1 ±0.1 percent, 7.7 ±0.2 percent [P = 0.02], and 8.1 ±0.3 percent [P<0.001], respectively).Ten patients died during the study period. Diabetic nephropathy developed in six of these patients: two died of end-stage renal disease, three died of end-stage renal failure accompanied by cardiovascular disease, and one died accidentally. Of the four patients without diabetic nephropathy who died, three died suddenly, possibly of hypoglycemia, and the fourth committed suicide.
Among the patients in the three groups for which 20 years of follow-up was available, four patients -- two in the group in which diabetes developed between 1961 and 1965 -- received antihypertensive treatment before the onset of diabetic nephropathy.
Discussion
In Sweden, all children with diabetes are treated at a hospital pediatric clinic; therefore, we are confident that all new cases of diabetes diagnosed in children between 1961 and 1980 were identified. The design of our study -- fixed groups based on the year of diagnosis of diabetes -- made it comparable with others4,5. Since we were able to follow most of the patients, our ascertainment of the incidence of diabetic nephropathy truly reflected the incidence among all patients with insulin-dependent diabetes. The definition of diabetic nephropathy (persistent proteinuria according to Albustix testing) was similar to that used in other studies4,5,8.
The incidence of persistent albuminuria changed over the years4,5. The cumulative incidence of 30 percent among the patients who had had diabetes for 25 years (after being given a diagnosis between 1961 and 1965) is similar to rates reported in the United States and Denmark4,5,8. The decline in the cumulative incidence to approximately 10 percent among patients in whom diabetes developed between 1966 and 1970 was unexpected. In two other studies, patients in whom diabetes developed between 1966 and 1980 had been followed only until the early 1980s4,5. The greater reduction in the incidence of persistent albuminuria in our study occurred during the latter part of the 1980s in patients whose diabetes was diagnosed between 1966 and 1980.
As in other studies,4,5 the incidence of diabetic nephropathy was highest among patients who had had diabetes for about 15 years. The patterns of the incidence curves in the various groups in our study were similar (Figure 1). With the reservation that the three groups of patients in which diabetes was diagnosed between 1966 and 1980 were followed for a relatively short period (11 to 26 years), the results suggest that albuminuria was prevented rather than delayed. Since the appearance of microalbuminuria is related to the later development of persistent albuminuria,9 the similarities among the four groups in the prevalence of microalbuminuria suggest that the differences in the incidence of persistent albuminuria will persist.
Patients with poor long-term glycemic control are more likely to have microalbuminuria10-13 and diabetic nephropathy14. Our patients with microalbuminuria or persistent albuminuria had higher mean glycosylated hemoglobin values than the patients in whom albumin excretion was not increased. The importance of strict metabolic control was emphasized in the 1970s and became a principal goal of our treatment. Improvement of glycemic control, reflected by glycosylated hemoglobin values of about 7.0 percent, as in this study, is associated with lower urinary albumin excretion15-17 and a decrease in the incidence of diabetic nephropathy18. The decline in the cumulative incidence of persistent albuminuria from 30.0 percent to 8.9 percent is therefore probably a result of improved glycemic control.
Treatment with antihypertensive drugs reduces microalbuminuria in patients with diabetes19,20. The decrease in the cumulative incidence of persistent albuminuria in our study was, however, not related to antihypertensive treatment, since only four patients without diabetic nephropathy were receiving such therapy, and two of them were in the group in which the incidence was highest.
If genetic factors are important in the development of diabetic nephropathy, they must work together with poor glycemic control, or the cumulative incidence of diabetic nephropathy would not have decreased in such an ethnically homogeneous group of patients as ours17,21-23.
Diabetic nephropathy in patients with insulin-dependent diabetes mellitus is associated with a high risk of early death,3 the relative mortality among patients with nephropathy being 40 times greater than that among those without it2. Our results confirm the magnitude of this risk: 6 of the 22 patients with nephropathy (27.3 percent) died, as compared with 4 of the 191 patients without nephropathy (2.1 percent). Once a patient has persistent albuminuria, treatment may not prevent progression to renal failure24. Effective treatment of coexistent hypertension seems to reduce renal and cardiovascular mortality among patients with albuminuria25. The cost of caring for American patients with diabetes in end-stage renal failure was about $2 billion in 19901. The reduction in the cumulative incidence of diabetic nephropathy from 30 percent to less than 10 percent among our patients who have had diabetes for 25 years has important implications for the individual patient, the provision of health care, and the costs of treatment of end-stage renal disease in patients with insulin-dependent diabetes mellitus.
Supported by Barndiabetes fonden (the Swedish Child Diabetes Foundation), the Swedish Diabetes Association, and research funds from the counties of Ostergotland and Jonkoping.
We are indebted to Professor Emeritus Yngve Larsson for initiating the study, to Dr. S.-G. Karlander, and to members of departments of internal medicine all over Sweden who provided us with patient data and hospital records, without which this study could not have been performed.
Source Information
From the Departments of Internal Medicine (M.B., H.J.A., B.E.K.) and Pediatrics (G.H., J.L.), University Hospital, Linkoping, Sweden, and the Department of Internal Medicine, Eksjo Hospital, Eksjo, Sweden (M.B.).
Address reprint requests to Dr. Bojestig at the Department of Medicine, Eksjo Hospital, S-575 81 Eksjo, Sweden.
- References
References
1
United States Renal Data System's 1990 Annual Data Report
Web of Science2
Borch-Johnsen K ,Andersen PK ,Deckert T . The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985;28:590-596
CrossRef | Web of Science | Medline3
Andersen AR ,Christiansen JS ,Andersen JK ,Kreiner S ,Deckert T . Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501
CrossRef | Web of Science | Medline4
Krolewski AS ,Warram JH ,Christlieb AR ,Busick EJ ,Kahn CR . The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-794
CrossRef | Web of Science | Medline5
Kofoed-Enevoldsen A ,Borch-Johnsen K ,Kreiner S ,Nerup J ,Deckert T . Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark. Diabetes 1987;36:205-209
CrossRef | Web of Science | Medline6
Ludvigsson J. Metabolic control in juvenile diabetes mellitus: the influence of some biochemical and socio-psychological factors. (Medical dissertation no. 42. Linkoping, Sweden: University of Linkoping, 1976).
7
SPSS Inc. SPSS for the Macintosh: operations guide. Chicago: SPSS Inc., 1990.
8
Orchard TJ ,Dorman JS ,Maser RE , et al. Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124
CrossRef | Web of Science | Medline9
Mogensen CE . Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-689
CrossRef | Web of Science | Medline10
Chase HP ,Jackson WE ,Hoops SL ,Cockerham RS ,Archer PG ,O'Brien D . Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989;261:1155-1160
CrossRef | Web of Science | Medline11
Norgaard K ,Storm B ,Graae M ,Feldt-Rasmussen B . Elevated albumin excretion ratio and retinal changes in children with type 1 diabetes are related to long-term poor blood glucose control. Diabet Med 1989;6:325-328
CrossRef | Web of Science | Medline12
Bangstad H-J ,Hanssen KF ,Dahl-Jorgensen K ,Aagenaes O . Microalbuminuria is associated with longterm poor glycemic control in adolescent insulin dependent diabetics. Diabetes Res 1989;12:71-74
Medline13
D'Antonio JA ,Ellis D ,Doft BH , et al. Diabetes complications and glycemic control: the Pittsburgh Prospective Insulin-Dependent Diabetes Cohort Study status report after 5 yr of IDDM. Diabetes Care 1989;12:694-700
CrossRef | Web of Science | Medline14
Klein R ,Klein BE ,Moss SE . The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus. Arch Intern Med 1991;151:1344-1348
CrossRef | Web of Science | Medline15
Reichard P ,Berglund B ,Britz A ,Cars I ,Nilsson BY ,Rosenqvist U . Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991;230:101-108
CrossRef | Web of Science | Medline16
Feldt-Rasmussen B ,Mathiesen ER ,Jensen T ,Lauritzen T ,Deckert T . Effect of improved metabolic control on loss of kidney function in insulin-dependent diabetic patients. Diabetologia 1991;34:164-170
CrossRef | Web of Science | Medline17
Hanssen KF ,Bangstad H-J ,Brinchmann-Hansen O ,Dahl-Jorgensen K . Blood glucose control and diabetic microvascular complications: long-term effects of near normoglycaemia. Diabet Med 1992;9:697-705
CrossRef | Web of Science | Medline18
Wang PH ,Lau J ,Chalmers TC . Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-1309
CrossRef | Web of Science | Medline19
Marre M ,Chatellier G ,Leblanc H ,Guyene TT ,Menard J ,Passa P . Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988;297:1092-1095
CrossRef | Web of Science | Medline20
Parving H-H ,Hommel E ,Damkjaer Nielsen M ,Giese J . Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 1989;299:533-536
CrossRef | Web of Science | Medline21
Krolewski AS ,Canessa M ,Warram JH , et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988;318:140-145
Full Text | Web of Science | Medline22
Borch-Johnsen K ,Norgaard K ,Hommel E , et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992;41:719-722
CrossRef | Web of Science | Medline23
Krolewski AS ,Warram JH ,Rand LI ,Kahn CR . Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317:1390-1398
Full Text | Web of Science | Medline24
Viberti GC ,Yip-Messent J ,Morocutti A . Diabetic nephropathy: future avenue. Diabetes Care 1992;15:1216-1225
CrossRef | Web of Science | Medline25
Mathiesen ER ,Borch-Johnsen K ,Jensen DV ,Deckert T . Improved survival in patients with diabetic nephropathy. Diabetologia 1989;32:884-886
CrossRef | Web of Science | Medline
- Citing Articles (126)
Citing Articles
1
Ludvigsson, Johnny, Krisky, David, Casas, Rosaura, Battelino, Tadej, Castaño, Luis, Greening, James, Kordonouri, Olga, Otonkoski, Timo, Pozzilli, Paolo, Robert, Jean-Jacques, Veeze, Henk J., Palmer, Jerry, . (2012) GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus. New England Journal of Medicine 366:5, 433-442
Full Text2
Wen-Jin Fu, Bao-Liang Li, Shao-Bo Wang, Mei-Lian Chen, Ren-Tang Deng, Chang-Qin Ye, Liang Liu, Ai-Juan Fang, Shi-Long Xiong, Shu Wen, Hui-Hua Tang, Zai-Xing Chen, Zhi-Hong Huang, Lan-Fen Peng, Lei Zheng, Qian Wang. (2011) Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Research and Clinical Practice
CrossRef3
Wen-jin Fu, Shi-long Xiong, Yao-gao Fang, Shu Wen, Mei-lian Chen, Ren-tang Deng, Lei Zheng, Shao-bo Wang, Lan-fen Pen, Qian Wang. (2011) Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine
CrossRef4
Raul Fechete, Andreas Heinzel, Paul Perco, Konrad Mönks, Johannes Söllner, Gil Stelzer, Susanne Eder, Doron Lancet, Rainer Oberbauer, Gert Mayer, Bernd Mayer. (2011) Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. PROTEOMICS - Clinical Applications 5:5-6, 354-366
CrossRef5
Kuan-Hsing Chen, Cheng-Chieh Hung, Hsiang-Hao Hsu, Yu-Hong Jing, Chih-Wei Yang, Jan-Kan Chen. (2011) Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chemico-Biological Interactions 190:1, 45-53
CrossRef6
Peter Rossing, Dick de Zeeuw. (2011) Need for better diabetes treatment for improved renal outcome. Kidney International 79, S28-S32
CrossRef7
J. Ludvigsson, M. Hjorth, M. Chéramy, S. Axelsson, M. Pihl, G. Forsander, N.-Ö. Nilsson, B.-O. Samuelsson, T. Wood, J. Åman, E. Örtqvist, R. Casas. (2011) Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54:3, 634-640
CrossRef8
Takahiko Nakagawa, Katsuyuki Tanabe, Byron P. Croker, Richard J. Johnson, Maria B. Grant, Tomoki Kosugi, Qiuhong Li. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nature Reviews Nephrology 7:1, 36-44
CrossRef9
Johnny Ludvigsson. (2011) Diabetes vaccines: review of the clinical evidence. Clinical Investigation 1:1, 157-169
CrossRef10
Stephen M. Twigg. (2010) Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease. Journal of Cell Communication and Signaling 4:4, 189-196
CrossRef11
Kevin V. Lemley. (2010) When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. Pediatric Nephrology 25:10, 2021-2034
CrossRef12
, Johnny Ludvigsson. (2010) Immune Intervention in Children with Type 1 Diabetes. Current Diabetes Reports 10:5, 370-379
CrossRef13
Toshikazu Araoka, Hideharu Abe, Tatsuya Tominaga, Akira Mima, Takeshi Matsubara, Taichi Murakami, Seiji Kishi, Kojiro Nagai, Toshio Doi. (2010) Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy. Molecules and Cells 30:3, 209-218
CrossRef14
Kim C. Donaghue, Francesco Chiarelli, Daniela Trotta, Jeremy Allgrove, Knut Dahl-Jorgensen. (2009) Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatric Diabetes 10, 195-203
CrossRef15
Andrew W. Norris, Joseph I. Wolfsdorf. 2009. Diabetes Mellitus. , 458-504.
CrossRef16
Maria Nordwall, Hans J Arnqvist, Mats Bojestig, Johnny Ludvigsson. (2009) Good glycemic control remains crucial in prevention of late diabetic complications - the Linköping Diabetes Complications Study. Pediatric Diabetes 10:3, 168-176
CrossRef17
Johnny Ludvigsson. (2009) Therapy with GAD in diabetes. Diabetes/Metabolism Research and Reviews 25:4, 307-315
CrossRef18
Tae-Sun Ha. (2009) Diabetic Nephropathy in Childhood and Adolescence (I) : Clinical Features. Journal of the Korean Society of Pediatric Nephrology 13:1, 1
CrossRef19
Toshio Doi, Akira Mima, Takeshi Matsubara, Tatsuya Tominaga, Hidenori Arai, Hideharu Abe. (2008) The current clinical problems for early phase of diabetic nephropathy and approach for pathogenesis of diabetic nephropathy. Diabetes Research and Clinical Practice 82, S21-S24
CrossRef20
Ludvigsson, Johnny, Faresjö, Maria, Hjorth, Maria, Axelsson, Stina, Chéramy, Mikael, Pihl, Mikael, Vaarala, Outi, Forsander, Gun, Ivarsson, Sten, Johansson, Calle, Lindh, Agne, Nilsson, Nils-Östen, Åman, Jan, Örtqvist, Eva, Zerhouni, Peter, Casas, Rosaura, . (2008) GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes. New England Journal of Medicine 359:18, 1909-1920
Full Text21
Pedro Iglesias, Juan J. Díez. (2008) Insulin therapy in renal disease. Diabetes, Obesity and Metabolism 10:10, 811-823
CrossRef22
Ulf Samuelsson, Ragnar Hanas, Per Arne Whiss, Johnny Ludvigsson. (2008) Do high blood glucose peaks contribute to higher HbA1c? Results from repeated continuous glucose measurements in children. World Journal of Pediatrics 4:3, 215-221
CrossRef23
Radovan Bogdanović. (2008) Diabetic nephropathy in children and adolescents. Pediatric Nephrology 23:4, 507-525
CrossRef24
Saeed Abdelwhab Saeed, Hamed Ellakwa. (2008) Pregnancy in Patients with Diabetic Nephropathy. Kidney 17:1, 10-17
CrossRef25
Lorenzo Pasquali, Massimo Trucco, Steven Ringquist. (2007) Navigating pathways affecting type 1 diabetic kidney disease. Pediatric Diabetes 8:5, 307-322
CrossRef26
Tomoki Kosugi, Yukio Yuzawa, Waichi Sato, Hanayo Arata-Kawai, Norihiko Suzuki, Noritoshi Kato, Seiichi Matsuo, Kenji Kadomatsu. (2007) Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Laboratory Investigation 87:9, 903-913
CrossRef27
Kim C Donaghue, Francesco Chiarelli, Daniela Trotta, Jeremy Allgrove, Knut Dahl-Jorgensen. (2007) Microvascular and macrovascular complications. Pediatric Diabetes 8:3, 163-170
CrossRef28
S. Nordfeldt, L. Hanberger, F. Malm, J. Ludvigsson. (2007) Development of a PC-Based Diabetes Simulator in Collaboration with Teenagers with Type 1 Diabetes. Diabetes Technology & Therapeutics 9:1, 17-25
CrossRef29
J. Hedbrant, S. Nordfeldt, J. Ludvigsson. (2007) The Särimner Diabetes Simulator—A Look in the Rear View Mirror. Diabetes Technology & Therapeutics 9:1, 10-16
CrossRef30
Peter Rossing. (2006) Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history. Current Diabetes Reports 6:6, 479-483
CrossRef31
2006. Post-Myocardial Infarction. .
CrossRef32
Torild Skrivarhaug, Hans-Jacob Bangstad, Lars C Stene, Leiv Sandvik, Kristian F Hanssen, Geir Joner. (2006) Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatric Diabetes 7:5, 239-246
CrossRef33
Ragnar Hanas, Johnny Ludvigsson. (2006) Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. Pediatric Diabetes 7:s4, 32-38
CrossRef34
Geoffrey R Ambler, Jan Fairchild, Maria E Craig, Fergus J Cameron. (2006) Contemporary Australian outcomes in childhood and adolescent type 1 diabetes: 10
years post the Diabetes Control and Complications Trial. Journal of Paediatrics and Child Health 42:7-8, 403-410
CrossRef35
Patricia Herold Gallego, Max Kishor Bulsara, Fiona Frazer, Antony Richard Lafferty, Elizabeth Ann Davis, Timothy William Jones. (2006) Prevalence and risk factors for microalbuminuria in a population-based sample of children and adolescents with T1DM in Western Australia. Pediatric Diabetes 7:3, 165-172
CrossRef36
Lena Hanberger, Johnny Ludvigsson, Sam Nordfeldt. (2006) Quality of care from the patient's perspective in pediatric diabetes care. Diabetes Research and Clinical Practice 72:2, 197-205
CrossRef37
N E S S Perrin, T B Torbjörnsdotter, G A Jaremko, U B Berg. (2006) The course of diabetic glomerulopathy in patients with type I diabetes: A 6-year follow-up with serial biopsies. Kidney International 69:4, 699-705
CrossRef38
Tomoki Kosugi, Yukio Yuzawa, Waichi Sato, Hanayo Kawai, Seiichi Matsuo, Yoshifumi Takei, Takashi Muramatsu, Kenji Kadomatsu. (2006) Growth Factor Midkine Is Involved in the Pathogenesis of Diabetic Nephropathy. The American Journal of Pathology 168:1, 9-19
CrossRef39
Scott G. Bryk, Michael L. Censullo, Louis K. Wagner, Lucho L. Rossman, Alan M. Cohen. (2006) Endovascular and Interventional Procedures in Obese Patients: A Review of Procedural Technique Modifications and Radiation Management. Journal of Vascular and Interventional Radiology 17:1, 27-33
CrossRef40
Carlton Joseph Young. 2005. Diabetic Nephropathy. , 399-425.
CrossRef41
Giuseppe Derosa, Maria A. Avanzini, Diego Geroldi, Roberto Fogari, Renata Lorini, Annalisa De Silvestri, Carmine Tinelli, Giorgio Rondini, Giuseppe d’Annunzio. (2005) Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Research and Clinical Practice 70:2, 119-125
CrossRef42
Sam Nordfeldt, Calle Johansson, Eric Carlsson, Jan-Åke Hammersjö. (2005) Persistent effects of a pedagogical device targeted at prevention of severe hypoglycaemia: A randomized, controlled study. Acta Paediatrica 94:10, 1395-1401
CrossRef43
PETER ROSSING, PHILIP HOUGAARD, HANS-HENRIK PARVING. (2005) Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study. Kidney International 68:4, 1446-1450
CrossRef44
MARK E COOPER, KARIN JANDELEIT-DAHM, MERLIN C THOMAS. (2005) Targets to retard the progression of diabetic nephropathy. Kidney International 68:4, 1439-1445
CrossRef45
Isabel Salinas, Ramón Romero. (2005) Hipercolesterolemia y nefropatía diabética, una asociación multifactorial. Medicina Clínica 125:11, 415-416
CrossRef46
P. Rossing. (2005) The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 48:8, 1439-1444
CrossRef47
E. A. M. Gale. (2005) Type 1 diabetes in the young: the harvest of sorrow goes on. Diabetologia 48:8, 1435-1438
CrossRef48
Akari Inada, Kojiro Nagai, Hidenori Arai, Jun-ichi Miyazaki, Keiko Nomura, Hiroshi Kanamori, Shinya Toyokuni, Yuichiro Yamada, Susan Bonner-Weir, Gordon C. Weir, Atsushi Fukatsu, Yutaka Seino. (2005) Establishment of a Diabetic Mouse Model with Progressive Diabetic Nephropathy. The American Journal of Pathology 167:2, 327-336
CrossRef49
KOJIRO NAGAI, TAKESHI MATSUBARA, AKIRA MIMA, ERIKO SUMI, HIROSHI KANAMORI, NORIYUKI IEHARA, ATSUSHI FUKATSU, MOTOKO YANAGITA, TORU NAKANO, YOSHIKAZU ISHIMOTO, TORU KITA, TOSHIO DOI, HIDENORI ARAI. (2005) Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney International 68:2, 552-561
CrossRef50
Matthias Meier, Thorsten Kaiser, Alena Herrmann, Stefan Knueppel, Meike Hillmann, Peer Koester, Thomas Danne, Hermann Haller, Danilo Fliser, Harald Mischak. (2005) Identification of urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. Journal of Diabetes and its Complications 19:4, 223-232
CrossRef51
Hongyu Jiang, Jason P. Fine, Rick Chappell. (2005) Semiparametric Analysis of Survival Data with Left Truncation and Dependent Right Censoring. Biometrics 61:2, 567-575
CrossRef52
G. Vervoort, B. Veldman, J. H. M. Berden, P. Smits, J. F. M. Wetzels. (2005) Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion. European Journal of Clinical Investigation 35:5, 330-336
CrossRef53
L. Hyllienmark, J. Maltez, A. Dandenell, J. Ludvigsson, T. Brismar. (2005) EEG abnormalities with and without relation to severe hypoglycaemia in adolescents with type 1 diabetes. Diabetologia 48:3, 412-419
CrossRef54
CP Schwarze, DB Dunger. (2005) Management of early diabetic nephropathy in adolescents with type 1 diabetes mellitus. Practical Diabetes International 22:2, 65-69
CrossRef55
G. Tryggvason, O. S. Indridason, A. V. Thorsson, A. B. Hreidarsson, R. Palsson. (2005) Unchanged incidence of diabetic nephropathy in Type 1 diabetes: a nation-wide study in Iceland. Diabetic Medicine 22:2, 182-187
CrossRef56
Sam Nordfeldt, Calle Johansson, Eric Carlsson, Jan-Åke Hammersjö. (2005) Persistent effects of a pedagogical device targeted at prevention of severe hypoglycaemia: A randomized, controlled study. Acta Paediatrica 94:10, 1395
CrossRef57
John N Harvey. (2004) The increasing incidence of childhood-onset type 1 diabetes. What are the implications?. Practical Diabetes International 21:7, 243-244
CrossRef58
JOHN H STEWART, MARGARET RE MCCREDIE, SHEILA M WILLIAMS, STEPHEN P MCDONALD. (2004) Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology 9:4, 238-246
CrossRef59
JOHN J FRIEDEWALD, HAMID RABB. (2004) Inflammatory cells in ischemic acute renal failure. Kidney International 66:2, 486-491
CrossRef60
Ali Jawa, Juanita Kcomt, Vivian A Fonseca. (2004) Diabetic nephropathy and retinopathy. Medical Clinics of North America 88:4, 1001-1036
CrossRef61
Stephen C. Jones, Sally M. Marshall, Rudy W. Bilous. 2004. Diabetic Nephropathy. .
CrossRef62
Kunihiro Yamagata, Hideto Takahashi, Soh Suzuki, Kaori Mase, Masahiro Hagiwara, Yoshio Shimizu, Kouichi Hirayama, Masaki Kobayashi, Mitsuharu Narita, Akio Koyama. (2004) Age distribution and yearly changes in the incidence of ESRD in Japan. American Journal of Kidney Diseases 43:3, 433-443
CrossRef63
J. N. Harvey, B. Allagoa. (2004) The long-term renal and retinal outcome of childhood-onset Type 1 diabetes. Diabetic Medicine 21:1, 26-31
CrossRef64
U.-B. Lofgren, U. Rosenqvist, T. Lindstrom, C. Hallert, F. H. Nystrom. (2004) Diabetes control in Swedish community dwelling elderly: more often tight than poor. Journal of Internal Medicine 255:1, 96-101
CrossRef65
L. Zhang, G. Krzentowski, A. Albert, P. J. Lefèbvre. (2003) Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. Diabetic Medicine 20:7, 580-585
CrossRef66
Rimei Nishimura, Janice S Dorman, Zsolt Bosnyak, Naoko Tajima, Dorothy J Becker, Trevor J Orchard. (2003) Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the allegheny county registry. American Journal of Kidney Diseases 42:1, 117-124
CrossRef67
John N. Harvey. (2003) Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Current Opinion in Nephrology and Hypertension 12:3, 317-322
CrossRef68
J Kirk, E Thomas, A McEvilly, N Shaw. (2003) Extension of a paediatric diabetes home care service. Practical Diabetes International 20:4, 125-128
CrossRef69
Alberto Verrotti, Daniela Trotta, Carmela Salladini, Madonna Laura, Francesco Chiarelli. (2003) Preventing microvascular diabetic complications in children and adolescents: looking beyond glycaemic control. Expert Opinion on Pharmacotherapy 4:4, 525-532
CrossRef70
Giacomo Deferrari, Maura Ravera, Valeria Berruti. (2003) Treatment of diabetic nephropathy in its early stages. Diabetes/Metabolism Research and Reviews 19:2, 101-114
CrossRef71
C. E. Kullberg, M. Abrahamsson, H. J. Arnqvist, K. Finnstrom, J. Ludvigsson. (2002) Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes. Diabetic Medicine 19:11, 924-931
CrossRef72
Giovanna di Corcia, Daniela Trotta, Alberto Verrotti, Francesco Chiarelli. (2002) New trends in the treatment of diabetic nephropathy in children. Expert Opinion on Pharmacotherapy 3:8, 1169-1176
CrossRef73
P. R. Betts, I. G. Jefferson, P. G. F. Swift. (2002) Diabetes care in childhood and adolescence. Diabetic Medicine 19:s4, 61-65
CrossRef74
Romana Klefter, Bent Nielsen. (2002) Savings in Dialysis Treatment?. Artificial Organs 26:1, 49-54
CrossRef75
J. N. Harvey, K. Rizvi, L. Craney, J. Messenger, R. Shah, P. A. Meadows. (2001) Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabetic Medicine 18:12, 998-1002
CrossRef76
Paola Fioretto, Maria Luiza Caramori, Michele Vestra, Michael Mauer. (2001) Risk predictors in patients with diabetic nephropathy. Current Diabetes Reports 1:3, 245-250
CrossRef77
John Wahren, Karin Ekberg, Björn Samnegård, Bo-Lennart Johansson. (2001) C-peptide: A new potential in the treatment of diabetic nephropathy. Current Diabetes Reports 1:3, 261-266
CrossRef78
Yasuhiko Yamamoto, Ichiro Kato, Toshio Doi, Hideto Yonekura, Seiji Ohashi, Masayoshi Takeuchi, Takuo Watanabe, Sho-ichi Yamagishi, Shigeru Sakurai, Shin Takasawa, Hiroshi Okamoto, Hiroshi Yamamoto. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. Journal of Clinical Investigation 108:2, 261-268
CrossRef79
L. Wibell, L. Nyström, J. Östman, H. Arnqvist, G. Blohmé, F. Lithner, B. Littorin, G. Sundkvist. (2001) Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15-34 years old at diagnosis. Journal of Internal Medicine 249:3, 263-270
CrossRef80
S Nordfeldt, D Jonsson. (2001) Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatrica 90:2, 137-142
CrossRef81
Stuart J. Brink. (2001) Complications of pediatric and adolescent type 1 diabetes mellitus. Current Diabetes Reports 1:1, 47-55
CrossRef82
Lars Hyllienmark, Helena Golster, Ulf Samuelsson, Johnny Ludvigsson. (2001) Nerve conduction defects are retarded by tight metabolic control in type I diabetes. Muscle & Nerve 24:2, 240-246
CrossRef83
Johan A Fagerudd, Kim J Pettersson-Fernholm, Mikael K Riska, Carola Grönhagen-Riska, Per-Henrik Groop. (2000) Albuminuria in nondiabetic relatives of IDDM patients with and without diabetic nephropathy. Kidney International 58:3, 959-965
CrossRef84
Hiroki Yokoyama, Maki Okudaira, Toshika Otani, Akiko Sato, Junnoske Miura, Hiroko Takaike, Hitomi Yamada, Kazuko Muto, Yasuko Uchigata, Yasuo Ohashi, Yasuhiko Iwamoto. (2000) Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney International 58:1, 302-311
CrossRef85
Päivi H. Riihimaa, Mikael Knip, Heli Hirvelä, Päivi Tapanainen. (2000) Metabolic characteristics and urine albumin excretion rate in relation to pubertal maturation in Type 1 diabetes. Diabetes/Metabolism Research and Reviews 16:4, 269-275
CrossRef86
C. LL. Morgan, C. J. Currie, N. C. H. Stott, M. Smithers, C. C. Butler, J. R. Peters. (2000) The prevalence of multiple diabetes-related complications. Diabetic Medicine 17:2, 146-151
CrossRef87
S Nordfeldt, J Ludvigsson. (1999) Adverse events in intensively treated children and adolescents with type 1 diabetes. Acta Paediatrica 88:11, 1184-1193
CrossRef88
The Microalbuminuria Collaborative Group. (1999) Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabetic Medicine 16:11, 918-925
CrossRef89
AHMET SARI, HASAN DINC, ALI ZIBANDEH, MÜNIR TELATAR, HALIT RESIT GÜMELE. (1999) Value of Resistive Index in Patients With Clinical Diabetic Nephropathy. Investigative Radiology 34:11, 718
CrossRef90
M Lövestam-Adrian, E Agardh, C.D Agardh. (1999) The temporal development of retinopathy and nephropathy in type 1 diabetes mellitus during 15 years diabetes duration. Diabetes Research and Clinical Practice 45:1, 15-23
CrossRef91
Hisham A.A. Ibrahim, Jiten P. Vora. (1999) Diabetic nephropathy. Best Practice & Research Clinical Endocrinology & Metabolism 13:2, 239-264
CrossRef92
S Nordfeldt, D Jonsson, J Ludvigsson. (1999) Increasing response rate in data registration and follow-up of children and adolescents with type 1 diabetes: A prospective population study 1992–97. Practical Diabetes International 16:4, 101-106
CrossRef93
JAN Carlström, GUNNELA Nordén, LARS Mjörnstedt, GUDRUN Nyberg. (1999) Increasing prevalence of cardiovascular disease in kidney transplant patients with Type 1 diabetes. Transplant International 12:3, 176-181
CrossRef94
Gérard E. Plante, Jude Alfred, Mouna Chakir. (1999) The blood vessel, linchpin of diabetic lesions. Metabolism 48:3, 406-409
CrossRef95
K Dahl-Jørgensen. (1999) Modern insulin therapy in children and adolescents. Acta Paediatrica 88:s427, 25-30
CrossRef96
Robert G Nelson, Hal Morgenstern, Peter H Bennett. (1998) An epidemic of proteinuria in Pima Indians with Type 2 diabetes mellitus. Kidney International 54:6, 2081-2088
CrossRef97
F Chiarelli, A Casani, A Verrotti, G Morgese, L Pinelli. (1998) Diabetic nephropathy in children and adolescents: a critical review with particular reference to angiotensin-converting enzyme inhibitors. Acta Paediatrica 87, 42-45
CrossRef98
HB Mortensen. (1998) Practical aspects of managing diabetes in adolescents. Acta Paediatrica 87, 72-76
CrossRef99
Matthew C. Riddle. (1997) TACTICS FOR TYPE II DIABETES. Endocrinology & Metabolism Clinics of North America 26:3, 659-677
CrossRef100
R. Hanas, J. Ludvigsson. (1997) Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Practical Diabetes International 14:4, 95-99
CrossRef101
PASCALE H. LANE. (1997) Age of Onset of Streptozocin Diabetes Determines the Renal Structural Response in the Rat. Pediatric Research 41:6, 912-915
CrossRef102
Miguel Harding S. Lapuz. (1997) DIABETIC NEPHROPATHY. Medical Clinics of North America 81:3, 679-688
CrossRef103
Peter Weidmann, Adrian U. Teuscher, Lorenz Böhlen. (1997) Treatment of elevated blood pressure in diabetic patients. Journal of Diabetes and its Complications 11:2, 92-99
CrossRef104
Rolf Renner. (1997) Individualisierte Insulininjektionstherapie des Typ-I-Diabetes mellitus. Medizinische Klinik 92:S1, 23-28
CrossRef105
Francesco Chiarelli, Alberto Verrotti, Angelika Mohn, Guido Morgese. (1997) The Importance of Microalbuminuria as an Indicator of Incipient Diabetic Nephropathy: Therapeutic Implications. Annals of Medicine 29:5, 439-445
CrossRef106
T.J. Franklin. (1997) Therapeutic approaches to organ fibrosis. The International Journal of Biochemistry & Cell Biology 29:1, 79-89
CrossRef107
Martin Krolewski, Paul W Eggers, James H Warram. (1996) Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study. Kidney International 50:6, 2041-2046
CrossRef108
Henrik Ekberg, Anders Christensson. (1996) Similar treatment success rate after renal transplantation in diabetic and nondiabetic patients due to improved short- and long-term diabetic patient survival. Transplant International 9:6, 557-564
CrossRef109
Amparo Lurbe, Paola Fioretto, Michael Mauer, Michael S LaPointe, Daniel Batlle. (1996) Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na+/H+ antiporter. Kidney International 50:5, 1684-1693
CrossRef110
T.A. Chowdhury, A.H. Barnett, S.C. Bain. (1996) Pathogenesis of diabetic nephropathy. Trends in Endocrinology & Metabolism 7:9, 320-323
CrossRef111
Terri J Allen, Mark E Cooper, Richard E Gilbert, Judy Winikoff, Sandford L Skinner, George Jerums. (1996) Serum total renin is increased before microalbuminuria in diabetes. Kidney International 50:3, 902-907
CrossRef112
Andrzej S. Krolewski, James H. Warram, Maria Beatriz S. Freire. (1996) EPIDEMIOLOGY OF LATE DIABETIC COMPLICATIONS. Endocrinology & Metabolism Clinics of North America 25:2, 217-242
CrossRef113
Demetrius Ellis, Cathy Lloyd, Dorothy J. Becker, Kimberly Y.-Z. Forrest, Trevor J. Orchard. (1996) The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. American Journal of Kidney Diseases 27:6, 809-818
CrossRef114
Barry M Brenner, Elizabeth V Lawler, Harald S Mackenzie. (1996) The hyperfiltration theory: A paradigm shift in nephrology. Kidney International 49:6, 1774-1777
CrossRef115
Enric Esmatjes, Conxa Castell, Teresa Gonzalez, Ricard Tresserras, Goncal Lloveras. (1996) Epidemiology of renal involvement in Type II diabetics (NIDDM) in Catalonia. Diabetes Research and Clinical Practice 32:3, 157-163
CrossRef116
J KITZMILLER, C COMBS. (1996) DIABETIC NEPHROPATHY AND PREGNANCY. Obstetrics and Gynecology Clinics of North America 23:1, 173-203
CrossRef117
Eberhard Ritz, Adam Stefanski. (1996) Diabetic nephropathy in type II diabetes. American Journal of Kidney Diseases 27:2, 167-194
CrossRef118
T. A. Chowdhury, S. Kumar, A. H. Barnett, S. C. Bain. (1995) Nephropathy in Type 1 Diabetes: the Role of Genetic Factors. Diabetic Medicine 12:12, 1059-1067
CrossRef119
R. Landgraf. (1995) Pancreatic Transplantation and its Future Role in Diabetes Management. Diabetic Medicine 12:11, 947-948
CrossRef120
Christopher D. Saudek. (1995) Non-ophthalmologic findings of the diabetes controland complications trial. Survey of Ophthalmology 40:2, 157-162
CrossRef121
G. Sartor, G. Dahlquist. (1995) Short-term Mortality in Childhood Onset Insulin-dependent Diabetes Mellitus: a High Frequency of Unexpected Deaths in Bed. Diabetic Medicine 12:7, 607-611
CrossRef122
Lee Goldman. (1995) Internal medicine update. Journal of General Internal Medicine 10:6, 331-341
CrossRef123
Wood, Alastair J.J., , Clark, Charles M. Jr., Lee, D. Anthony, . (1995) Prevention and Treatment of the Complications of Diabetes Mellitus. New England Journal of Medicine 332:18, 1210-1217
Full Text124
L. Hyllienmark, T. Brismar, J. Ludvigsson. (1995) Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia 38:6, 685
CrossRef125
Tim Dornan. (1994) Whither Secondary Care?. Diabetic Medicine 11:9, 822-824
CrossRef126
R. Mangili, G. Deferrari, U. Mario, O. Giampietro, R. Navalesi, R. Nosadini, G. Rigamonti, R. Spezia, G. Crepaldi, . (1994) Arterial hypertension and microalbuminuria in IDDM: The Italian Microalbuminuria Study. Diabetologia 37:10, 1015-1024
CrossRef
